Quarterly Activities Report and Appendix 4C

• HMBD-002 granted pINN 'minperstobart' by WHO
• New batch of drug substance completed
• $2.2 million raised through entitlement offer
• HMBD-002 posters presented at AACR and ASCO

Percheron Therapeutics Limited, an international biotechnology company, reported several key developments in its quarterly activities. HMBD-002, the company's lead drug, was granted a provisional International Non-Proprietary Name (pINN) 'minperstobart' by the World Health Organization (WHO). The manufacture of a new batch of HMBD-002 drug substance has been completed, with the material expected to be released for a new clinical trial in September 2026. The company raised $2.2 million through a non-renounceable entitlement offer, which will be used to progress the HMBD-002 program and for working capital. HMBD-002 abstracts were presented at the American Association for Cancer Research (AACR) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting, receiving positive feedback from clinicians and researchers.